<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for http://feeds.benzinga.com/benzinga</title><link>http://feeds.benzinga.com/benzinga</link><description>Individual feed output.</description><lastBuildDate>Mon, 29 Dec 2025 11:02:13 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Dow Falls Over 100 Points; US Pending Home Sales Rise In November</title><link>https://www.benzinga.com/markets/market-summary/25/12/49611367/dow-falls-over-100-points-us-pending-home-sales-rise-in-november</link><image_url>https://cdn.benzinga.com/files/images/story/2025/12/29/Tallinn--Estonia---August-4th-2023---Scr.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>read more</description><pubDate>Mon, 29 Dec 2025 15:19:02 GMT</pubDate></item><item><title>If You Invested $100 In Kinder Morgan Stock 5 Years Ago, You Would Have This Much Today</title><link>https://www.benzinga.com/insights/news/25/12/49611280/if-you-invested-100-in-kinder-morgan-stock-5-years-ago-you-would-have-this-much-today</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png</image_url><description>read more</description><pubDate>Mon, 29 Dec 2025 15:17:08 GMT</pubDate></item><item><title>Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows</title><link>https://www.benzinga.com/news/health-care/25/12/49611215/ultragenyx-mereo-bone-drug-trial-disappoints-stocks-hit-52-week-lows</link><image_url>https://cdn.benzinga.com/files/images/story/2025/12/29/Market--Down--Creative-Crash-Recession-C.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta treatment. read more</description><pubDate>Mon, 29 Dec 2025 15:15:16 GMT</pubDate></item><item><title>Sam Altman Says He's 'Envious of the Current Generation of 20-Year-Old Dropouts'</title><link>https://www.benzinga.com/personal-finance/financial-advisors/25/12/49610527/sam-altman-says-hes-envious-of-the-current-generation-of-20-year-old-dropouts</link><image_url>https://cdn.benzinga.com/files/images/story/2025/12/29/Openai-Ceo-Sam-Altman-Attends-The-Artifi_0.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Sam Altman, CEO of OpenAI, expressed his admiration for the entrepreneurial success of Gen Z college dropouts. read more</description><pubDate>Mon, 29 Dec 2025 15:01:22 GMT</pubDate></item><item><title>Analyzing Intel In Comparison To Competitors In Semiconductors &amp;amp; Semiconductor Equipment Industry</title><link>https://www.benzinga.com/insights/news/25/12/49610537/analyzing-intel-in-comparison-to-competitors-in-semiconductors-amp-semiconductor-equipment-industry</link><image_url>https://cdn.benzinga.com/files/images/story/2025/11/06/earnings_preview_1.jpg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>read more</description><pubDate>Mon, 29 Dec 2025 15:01:16 GMT</pubDate></item></channel></rss>